Legal & General Group PLC Anavex Life Sciences Corp. Transaction History

Legal & General Group PLC

$440 Billion
Q2 2024

A detailed history of Legal & General Group PLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Legal & General Group PLC holds 6,600 shares of AVXL stock, worth $35,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,600

Previous 71,087 90.72%

Holding current value

$35,904

Previous $361,000 92.52%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $218,610 - $323,724	-64,487 Reduced 90.72%	6,600 $27,000
Q1 2024 Jul 01, 2024	BUY	$4.55 - $6.75 $9,413 - $13,965	2,069 Added 3.0%	71,087 $361,000
Q1 2024 May 14, 2024	SELL	$4.55 - $6.75 $10,260 - $15,221	-2,255 Reduced 3.16%	69,018 $351,000
Q4 2023 Feb 15, 2024	SELL	$5.04 - $9.95 $1,013 - $1,999	-201 Reduced 0.28%	71,273 $663,000
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $5,423 - $7,758	828 Added 1.17%	71,474 $468,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $250,527 - $310,707	32,706 Added 86.2%	70,646 $574,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $14,892 - $21,032	1,790 Added 4.95%	37,940 $325,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $8,499 - $16,031	1,111 Added 3.17%	36,150 $334,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $13,198 - $19,071	1,483 Added 4.42%	35,039 $362,000
Q2 2022 Aug 22, 2022	BUY	$7.31 - $12.84 $12,697 - $22,303	1,737 Added 5.46%	33,556 $336,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $5,960 - $10,826	612 Added 1.96%	31,819 $392,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $20,272 - $27,995	1,201 Added 4.0%	31,207 $541,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $335,390 - $513,455	19,940 Added 198.09%	30,006 $538,000
Q2 2021 Aug 12, 2021	BUY	$10.16 - $28.86 $37,165 - $105,569	3,658 Added 57.08%	10,066 $231,000
Q1 2021 May 17, 2021	BUY	$5.17 - $16.13 $816 - $2,548	158 Added 2.53%	6,408 $96,000
Q4 2020 Feb 12, 2021	SELL	$4.01 - $7.58 $669 - $1,265	-167 Reduced 2.6%	6,250 $34,000
Q3 2020 Nov 13, 2020	SELL	$3.8 - $5.0 $7,185 - $9,455	-1,891 Reduced 22.76%	6,417 $29,000
Q2 2020 Aug 14, 2020	BUY	$2.62 - $5.2 $1,016 - $2,017	388 Added 4.9%	8,308 $41,000
Q1 2020 May 14, 2020	SELL	$2.38 - $5.81 $1,827 - $4,462	-768 Reduced 8.84%	7,920 $25,000
Q4 2019 Feb 13, 2020	BUY	$2.31 - $3.14 $3,511 - $4,772	1,520 Added 21.21%	8,688 $22,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $19,712 - $26,521	7,168 New	7,168 $24,000
Q2 2018 Aug 10, 2018	SELL	$2.08 - $4.26 $12,007 - $24,592	-5,773 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$3.12 - $4.94 $18,011 - $28,518	5,773	5,773 $19,000

Others Institutions Holding AVXL

# of Institutions

152

Shares Held

26.5M

Call Options Held

674K

Put Options Held

811K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $424M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Anavex Life Sciences Corp. Transaction History